Yellow Webinars
Il lancio degli YELLOW WEBINARS aggiunge un’importante attività al ruolo multitasking la Fondazione Italiana Fegato. Poiché la pandemia del 2020 ha cambiato sostanzialmente le nostre vite, abbiamo deciso di trasformare i tradizionali Yellow Seminars in presenza in Yellow Webinars consentendo alla FIF di diffondere meglio e ampiamente il messaggio scientifico . La qualità dei relatori e la rilevanza degli argomenti sono autoesplicativi.
Gli Yellow Webinars si terranno sulla nostra piattaforma Zoom
_____________
The launch of the YELLOW WEBINARS adds an important activity to the multitasking role of the Italian Liver Foundation. Since the 2020 pandemic has substantially changed our lives, we have decided to transform the traditional Yellow Seminars in presence into Yellow Webinars allowing the FIF to better and widely disseminate the scientific message. The quality of the speakers and the relevance of the topics are self-explanatory.
The Yellow Webinars will be held on our Zoom platform
Zoom ID : 454 870 8300
pw: liver
January 13, 2025
2.00 p.m. CET
Metabolic alterations in MASLD: lipids but also glucose
Amalia Gastaldelli, PhD
Research Director of Cardiometabolic Risk Unit
Institute of Clinical Physiology, CNR Pisa Italy
Professor of Medicine-adjunct, UT Medical Center San Antonio TX, USA
Professor-Adjunct Scuola Superiore Sant’Anna Pisa
February 10, 2025
2.00 p.m. CET
Advancing Pediatric Cancer Research
Group Leader, Princess Maxima Center for Pediatric Oncology
Research Chair, Maxima Comprehensive Childhood Cancer Center Liver Tumor Group
Utrecht, The Netherlands
March 3, 2025
2.00 p.m. CET
Generative Artificial Intelligence in Hepatology
Mauro Giuffrè
Specialist in Digestive Diseases
Postdoctoral Fellow at Yale School of Medicine
Department of Internal Medicine
Section of Digestive Diseases
March 31, 2025
2.00 p.m. CET
Cholestatic liver disease – PBC and PSC
Andreas Teufel
Professor of Hepatology, Division of Hepatology,
Department of Internal Medicine II, Medical Faculty Mannheim,
Heidelberg University, Germany
April 14, 2025
2.00 p.m. CET
Hepatic Mitochondrial SAB level modulates Mitochondrial Stress, Steatohepatitis, Metabolic Syndrome, and Hepatic Fibrosis
Sanda Win, MD, PhD,
Assistant Professor
Department of Medicine
Division of Gastroenterological and Liver Diseases
Keck School of Medicine
University of Southern California
May 5, 2025
2.00 p.m. CET
Estimating presence of liver disease due to SLD
and risk of future cirrhosis in the general population
Hannes Hagström, MD, PhD
Professor, Karolinska Institutet
Consultant hepatologist,
Karolinska University Hospital,
Stockholm, Sweden
May 19, 2025
2.00 p.m. CET
Metabolic dysfunction-associated steatotic liver disease (MASLD), cardiovascular and chronic kidney disease risk, and new treatments
Chris D Byrne, MB BCh PhD
Professor Endocrinology & Metabolism
University of Southampton &
University Hospital Southampton, UK
June 16, 2025
2.00 p.m. CET
News about neonatal jaundice diagnosis and management
Prof. Daniele DE LUCA (MD,PhD)
Full Professor of Pediatrics (Neonatology)
Division Chief, Pediatrics, Transportation and Neonatal Critical Care
Immediate Past President – European Society for Pediatric and Neonatal Intensive Care (ESPNIC)
Editor – European Journal of Pediatrics
AP-HP Université Paris Saclay “A. Béclère” Medical center
& INSERM Research Unit U999 “Physiopathology and Therapeutic Innovation”
June 31, 2025
2.00 p.m. CET
Metabolic changes in hepatic steatosis and their effect on drug toxicity
Principal Investigator – Liver Metabolism Lab,
Department of Molecular Biology, Ariel University, Israel